Cargando…

Myocardial Injury After Ischemia/Reperfusion Is Attenuated By Pharmacological Galectin-3 Inhibition

Although optimal therapy for myocardial infarction includes reperfusion to restore blood flow to the ischemic region, ischemia/reperfusion (IR) also initiates an inflammatory response likely contributing to adverse left ventricular (LV) extracellular matrix (ECM) remodeling. Galectin-3 (Gal-3), a β-...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibarrola, Jaime, Matilla, Lara, Martínez-Martínez, Ernesto, Gueret, Alexandre, Fernández-Celis, Amaya, Henry, Jean-Paul, Nicol, Lionel, Jaisser, Frederic, Mulder, Paul, Ouvrard-Pascaud, Antoine, López-Andrés, Natalia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610618/
https://www.ncbi.nlm.nih.gov/pubmed/31270370
http://dx.doi.org/10.1038/s41598-019-46119-6
_version_ 1783432535872634880
author Ibarrola, Jaime
Matilla, Lara
Martínez-Martínez, Ernesto
Gueret, Alexandre
Fernández-Celis, Amaya
Henry, Jean-Paul
Nicol, Lionel
Jaisser, Frederic
Mulder, Paul
Ouvrard-Pascaud, Antoine
López-Andrés, Natalia
author_facet Ibarrola, Jaime
Matilla, Lara
Martínez-Martínez, Ernesto
Gueret, Alexandre
Fernández-Celis, Amaya
Henry, Jean-Paul
Nicol, Lionel
Jaisser, Frederic
Mulder, Paul
Ouvrard-Pascaud, Antoine
López-Andrés, Natalia
author_sort Ibarrola, Jaime
collection PubMed
description Although optimal therapy for myocardial infarction includes reperfusion to restore blood flow to the ischemic region, ischemia/reperfusion (IR) also initiates an inflammatory response likely contributing to adverse left ventricular (LV) extracellular matrix (ECM) remodeling. Galectin-3 (Gal-3), a β-galactoside-binding-lectin, promotes cardiac remodeling and dysfunction. Our aim is to investigate whether Gal-3 pharmacological inhibition using modified citrus pectin (MCP) improves cardiac remodeling and functional changes associated with IR. Wistar rats were treated with MCP from 1 day before until 8 days after IR (coronary artery ligation) injury. Invasive hemodynamics revealed that both LV contractility and LV compliance were impaired in IR rats. LV compliance was improved by MCP treatment 8 days after IR. Cardiac magnetic resonance imaging showed decreased LV perfusion in IR rats, which was improved with MCP. There was no difference in LV hypertrophy in MCP-treated compared to untreated IR rats. However, MCP treatment decreased the ischemic area as well as Gal-3 expression. Gal-3 blockade paralleled lower myocardial inflammation and reduced fibrosis. These novel data showing the benefits of MCP in compliance and ECM remodeling in IR reinforces previously published data showing the therapeutic potential of Gal-3 inhibition.
format Online
Article
Text
id pubmed-6610618
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-66106182019-07-15 Myocardial Injury After Ischemia/Reperfusion Is Attenuated By Pharmacological Galectin-3 Inhibition Ibarrola, Jaime Matilla, Lara Martínez-Martínez, Ernesto Gueret, Alexandre Fernández-Celis, Amaya Henry, Jean-Paul Nicol, Lionel Jaisser, Frederic Mulder, Paul Ouvrard-Pascaud, Antoine López-Andrés, Natalia Sci Rep Article Although optimal therapy for myocardial infarction includes reperfusion to restore blood flow to the ischemic region, ischemia/reperfusion (IR) also initiates an inflammatory response likely contributing to adverse left ventricular (LV) extracellular matrix (ECM) remodeling. Galectin-3 (Gal-3), a β-galactoside-binding-lectin, promotes cardiac remodeling and dysfunction. Our aim is to investigate whether Gal-3 pharmacological inhibition using modified citrus pectin (MCP) improves cardiac remodeling and functional changes associated with IR. Wistar rats were treated with MCP from 1 day before until 8 days after IR (coronary artery ligation) injury. Invasive hemodynamics revealed that both LV contractility and LV compliance were impaired in IR rats. LV compliance was improved by MCP treatment 8 days after IR. Cardiac magnetic resonance imaging showed decreased LV perfusion in IR rats, which was improved with MCP. There was no difference in LV hypertrophy in MCP-treated compared to untreated IR rats. However, MCP treatment decreased the ischemic area as well as Gal-3 expression. Gal-3 blockade paralleled lower myocardial inflammation and reduced fibrosis. These novel data showing the benefits of MCP in compliance and ECM remodeling in IR reinforces previously published data showing the therapeutic potential of Gal-3 inhibition. Nature Publishing Group UK 2019-07-03 /pmc/articles/PMC6610618/ /pubmed/31270370 http://dx.doi.org/10.1038/s41598-019-46119-6 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Ibarrola, Jaime
Matilla, Lara
Martínez-Martínez, Ernesto
Gueret, Alexandre
Fernández-Celis, Amaya
Henry, Jean-Paul
Nicol, Lionel
Jaisser, Frederic
Mulder, Paul
Ouvrard-Pascaud, Antoine
López-Andrés, Natalia
Myocardial Injury After Ischemia/Reperfusion Is Attenuated By Pharmacological Galectin-3 Inhibition
title Myocardial Injury After Ischemia/Reperfusion Is Attenuated By Pharmacological Galectin-3 Inhibition
title_full Myocardial Injury After Ischemia/Reperfusion Is Attenuated By Pharmacological Galectin-3 Inhibition
title_fullStr Myocardial Injury After Ischemia/Reperfusion Is Attenuated By Pharmacological Galectin-3 Inhibition
title_full_unstemmed Myocardial Injury After Ischemia/Reperfusion Is Attenuated By Pharmacological Galectin-3 Inhibition
title_short Myocardial Injury After Ischemia/Reperfusion Is Attenuated By Pharmacological Galectin-3 Inhibition
title_sort myocardial injury after ischemia/reperfusion is attenuated by pharmacological galectin-3 inhibition
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610618/
https://www.ncbi.nlm.nih.gov/pubmed/31270370
http://dx.doi.org/10.1038/s41598-019-46119-6
work_keys_str_mv AT ibarrolajaime myocardialinjuryafterischemiareperfusionisattenuatedbypharmacologicalgalectin3inhibition
AT matillalara myocardialinjuryafterischemiareperfusionisattenuatedbypharmacologicalgalectin3inhibition
AT martinezmartinezernesto myocardialinjuryafterischemiareperfusionisattenuatedbypharmacologicalgalectin3inhibition
AT gueretalexandre myocardialinjuryafterischemiareperfusionisattenuatedbypharmacologicalgalectin3inhibition
AT fernandezcelisamaya myocardialinjuryafterischemiareperfusionisattenuatedbypharmacologicalgalectin3inhibition
AT henryjeanpaul myocardialinjuryafterischemiareperfusionisattenuatedbypharmacologicalgalectin3inhibition
AT nicollionel myocardialinjuryafterischemiareperfusionisattenuatedbypharmacologicalgalectin3inhibition
AT jaisserfrederic myocardialinjuryafterischemiareperfusionisattenuatedbypharmacologicalgalectin3inhibition
AT mulderpaul myocardialinjuryafterischemiareperfusionisattenuatedbypharmacologicalgalectin3inhibition
AT ouvrardpascaudantoine myocardialinjuryafterischemiareperfusionisattenuatedbypharmacologicalgalectin3inhibition
AT lopezandresnatalia myocardialinjuryafterischemiareperfusionisattenuatedbypharmacologicalgalectin3inhibition